ORIC Pharmaceuticals Inc. (ORIC)
8.01
-0.02 (-0.25%)
At close: Mar 03, 2025, 12:41 PM
ORIC Pharmaceuticals Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | n/a | 1.03M | 966K | 897K | 970K | 1M | 900K | 900K |
| Gross Profit | n/a | -1.03M | -966K | -897K | -970K | -1M | -900K | -900K |
| Operating Income | -142.9M | -110.78M | -91.77M | -78.87M | -74.19M | -28.57M | -22.37M | -22.54M |
| Interest Income | n/a | 10.08M | 2.65M | 141K | 306K | 1.4M | 775K | 251K |
| Pretax Income | -127.85M | -100.7M | -89.12M | -78.72M | -73.7M | -26.88M | -21.36M | -22.03M |
| Net Income | -127.85M | -100.7M | -91.48M | -77.68M | -97.27M | -25.49M | -21.36M | -22.03M |
| Selling & General & Admin | 28.82M | 25.61M | 25.09M | 22.01M | 13.42M | 5.72M | 3.35M | 2.52M |
| Research & Development | 114.07M | 85.17M | 61.68M | 56.86M | 35.92M | 22.84M | 19.03M | 19.13M |
| Other Expenses | n/a | n/a | 5M | 15K | 177K | 289K | 233K | n/a |
| Operating Expenses | 142.9M | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 21.64M |
| Interest Expense | n/a | n/a | 2.65M | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -900K |
| Cost & Expenses | n/a | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 22.54M |
| Income Tax | n/a | n/a | 2.35M | -1.04M | 23.57M | -1.4M | -1.01M | n/a |
| Shares Outstanding (Basic) | 69.73M | 51.45M | 39.66M | 37.95M | 21.94M | 29.9M | 19.14M | 29.9M |
| Shares Outstanding (Diluted) | 69.73M | 51.45M | 39.66M | 37.95M | 21.94M | 29.9M | 19.14M | 29.9M |
| EPS (Basic) | -1.83 | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| EPS (Diluted) | -1.83 | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| EBITDA | -142.9M | -109.75M | -91.77M | -77.97M | -74.19M | -27.54M | -20.46M | -21.13M |
| Depreciation & Amortization | n/a | 1.03M | 966K | 897K | 970K | 1M | 900K | 900K |